Ticagrelor

Ticagrelor, produced by AstraZeneca, is an inhibitor of platelet aggregation. Unlike clopidogrel, ticagrelor is not a prodrug required metabolic activation. The drug was approved for use in the European Union by the European Commission on December 3, 2010, and by the US FDA on July 20, 2011. Its trade names are Brilinta (US), Brilique(EU) and Possia(EU).

Price Not Available 50 mg Ticagrelor Supplier Page

Catalog Number	T0179
Alternative Name(s)	AR-C 126532XX , AZD6140
Research Area	Metabolism\|\|\|Neuroscience\|\|\|GPCR/G Protein
Molecular Formula	C23H28F2N6O4S
CAS#	274693-27-5
Purity	100.00%
SMILES	CCCSc1nc2c(nnn2[C@@H]2C[C@H](OCCO)[C@@H](O)[C@H]2O)c(N[C@@H]2C[C@H]2c2cc(F)c(F)cc2)n1
Size	50 mg
Supplier Page	https://www.targetmol.com/compound/Ticagrelor
Additional Information	https://www.targetmol.com/datasheet/T0179